VitD3 Supplementation in Patients With Multiple Myeloma

The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.

Trial Details

NCT ID
NCT05846880
Phase
EARLY_PHASE1
Sponsor
Amany Keruakous, MD, MS.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Lenalidomide
  • Maintenance Vitamin D
  • No maintenance Vitamin D
Locations (sample)
  • Augusta, Georgia, United States|33.47097,-81.97484

Key Eligibility Criteria

  • Patients must be ≥ 18 years of age at time of registration to Step 1.
  • Patients must have history and physical exam within 28 days prior to registration.
  • Patients must have Zubrod/ECOG Performance Status ≤ 2.
  • Patients must have had a confirmed diagnosis of symptomatic MM (See Section 4.1) with measurable disease at the time of myeloma diagnosis that requ…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →